Matrix metalloproteinase-19 (MMP19)

Matrix metalloproteinase-19 (MMP19) is a secreted zinc-dependent endopeptidase belonging to the matrix metalloproteinase family, which plays a key role in extracellular matrix (ECM) breakdown during normal physiological processes such as embryonic development, reproduction, tissue remodeling, and wound healing, as well as in pathological conditions including arthritis and cancer metastasis[1][3][4]. MMP19 is synthesized as an inactive proenzyme and activated by proteolytic cleavage. It acts on a broad spectrum of ECM substrates including collagen type IV, laminin, fibronectin, cartilage oligomeric matrix protein, and aggrecan, and is involved in regulating cell proliferation, migration, angiogenesis, and adhesion[1][3]. Its expression and dysregulation are implicated in various diseases, such as certain cancers, arthritis, cardiovascular disease, and rare ocular anomalies[1][2][3][4].

Other names

Matrix metalloproteinase-19MMP19MMP-19matrix metalloproteinase RASIMMP18MMP-18RASIRASI-1CODAmatrix metalloproteinase-beta19

Inhibition of catalytic zinc-dependent protease activity (applies for matrix metalloproteinase inhibitors targeting MMPs generally)